Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Aug 23:12:715877.
doi: 10.3389/fendo.2021.715877. eCollection 2021.

Metabolic Functions of G Protein-Coupled Receptors and β-Arrestin-Mediated Signaling Pathways in the Pathophysiology of Type 2 Diabetes and Obesity

Camila Oliveira de Souza  1 , Xuenan Sun  1 , Dayoung Oh  1
Affiliations
Review

Metabolic Functions of G Protein-Coupled Receptors and β-Arrestin-Mediated Signaling Pathways in the Pathophysiology of Type 2 Diabetes and Obesity

Camila Oliveira de Souza et al. Front Endocrinol (Lausanne). .

Abstract

Seven transmembrane receptors (7TMRs), often termed G protein-coupled receptors (GPCRs), are the most common target of therapeutic drugs used today. Many studies suggest that distinct members of the GPCR superfamily represent potential targets for the treatment of various metabolic disorders including obesity and type 2 diabetes (T2D). GPCRs typically activate different classes of heterotrimeric G proteins, which can be subgrouped into four major functional types: Gαs, Gαi, Gαq/11, and G12/13, in response to agonist binding. Accumulating evidence suggests that GPCRs can also initiate β-arrestin-dependent, G protein-independent signaling. Thus, the physiological outcome of activating a certain GPCR in a particular tissue may also be modulated by β-arrestin-dependent, but G protein-independent signaling pathways. In this review, we will focus on the role of G protein- and β-arrestin-dependent signaling pathways in the development of obesity and T2D-related metabolic disorders.

Keywords: GPCRs; biased signaling; obesity; type 2 diabetes; β-arrestins.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Expression and function of various GPCRs in metabolic tissues. Various GPCRs target insulin resistance, obesity, and T2D-related pathophysiology in the metabolic tissues. KA, kynurenic acid; LCFA, long-chain fatty acid; SCFA, short-chain fatty acid; OEA, oleylethanolamide; PUFA, polyunsaturated fatty acid; CCK, cholecystokinin; GLP-1, glucagon-like peptide 1; GIP, gastric inhibitory polypeptide.
Figure 2
Figure 2
The concept of GPCR signaling: biased signaling. (A) G protein-biased agonist. Biased agonists selectively activate the GPCR-dependent signaling pathway. Previous studies demonstrate that sustained G protein-mediated signaling can affect cellular response through second messenger activation. (B) β-Arrestin biased agonist. Biased agonists selectively activate the β-arrestin-dependent signaling pathway. The β-arrestin-mediated signaling leads to distinct physiological outcomes. (C) Balanced agonist. Balanced agonists activate both the G protein- and β-arrestin-dependent signaling pathway.
See this image and copyright information in PMC

References

    1. Control CfD, Prevention . National Diabetes Statistics Report, 2020. Atlanta, GA: Centers for Disease Control and Prevention, US Department of Health and Human Services; (2020) p. 12–5.
    1. Kahn SE, Hull RL, Utzschneider KM. Mechanisms Linking Obesity to Insulin Resistance and Type 2 Diabetes. Nature (2006) 444(7121):840–6. 10.1038/nature05482 - DOI - PubMed
    1. Barnes AS. The Epidemic of Obesity and Diabetes: Trends and Treatments. Texas Heart Institute J (2011) 38(2):142–4. - PMC - PubMed
    1. Cerf ME. Beta Cell Dysfunction and Insulin Resistance. Front Endocrinol (2013) 4:37. 10.3389/fendo.2013.00037 - DOI - PMC - PubMed
    1. Prentki M, Nolan CJ. Islet Beta Cell Failure in Type 2 Diabetes. J Clin Invest (2006) 116(7):1802–12. 10.1172/JCI29103 - DOI - PMC - PubMed

Publication types

MeSH terms

Substances